Skip to content

Application of alfentanil combined with remazolam in hysteroscopic surgery

Application of alfentanil combined with remazolam in hysteroscopic surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063434
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-08-24
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proper use of anesthetics

Interventions

group ARP:Anesthesia with alfentanil, Remimazolam and propofol
group FP:Anesthesia with fentanyl and propofol

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 12 years, ASA grade I-III; 2. Patients undergoing general anesthesia without endotracheal intubation; 3. In line with ethics, patients voluntarily took the test and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Unable to communicate effectively with researchers; 2. Complicated with serious organic diseases such as brain, heart, liver and kidney; 3. Suspected long-term use or abuse of narcotic sedative and analgesic drugs; 4. Patients with anaesthetic drug allergy or anesthesia method contraindication.

Design outcomes

Primary

MeasureTime frame
NRS, numerical rating scale;The American Pain Societies, Patient Outcome Questionnaire, Revised edition (APS-POQ-R) scale;Observer's assessment of alertness/sedation (OAA/S) scale;SBP, systolic blood pressure;DBP, diastolic blood pressure;ABP, Average blood pressure;HR, heart rate;Duration of resuscitation;Post anesthesia care unit (PACU) stay;perioperative adverse reactions;

Secondary

MeasureTime frame
Alderete score;Mini-mental State Examination (MMSE) scale;SpO2;Usage of propofol;Duration of operation;

Countries

China

Contacts

Public ContactPan Sining

The First Affiliated Hospital of Guangxi Medical University

447070480@qq.com+86 13977186724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026